Introduction
Gliomas are the most common type of primary brain tumor in humans, accounting for >80% of all brain malignancies (1) . Gliomas are classified into astrocytomas (Grade I-IV), oligodendrogliomas (Grade II and III), ependymomas (Grade I-III) and mixed oligo-astrocytomas (Grade II and III), according to the World Health Organization (1, 2) . Glioblastoma, also termed glioblastoma multiforme, is a Grade IV astrocytoma, which is the most aggressive form of glioma, and accounts for ~60-70% of all malignant gliomas worldwide (1, 3) . The prognosis for patients diagnosed with glioblastoma is particularly poor, with 1-year and 5-year survival rates at ~36% and 5%, respectively (1, 4) . Current treatments for malignant gliomas include maximal surgical resection whenever possible, radiotherapy and chemotherapy, however, no significant improvements in survival rates have been achieved (5) and there remains urgent requirement for the identification of novel molecular targets and therapies.
Insulin-like growth factor I receptor (IGF-1R) is a tyrosine kinase receptor, which binds to IGF1 and IGF2. Upon ligand binding, IGF-1R activates the Ras/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways and regulates cell proliferation and survival (6) . The IGF/IGF-1R signaling axis has been implicated in the development of several types of solid tumor by promoting the growth and survival of malignant cells (7) (8) (9) . Previous studies have demonstrated that this pathway is also involved in the development of gliomas (10) (11) (12) (13) (14) . Therefore, the IGF/IGF-1R signaling pathway may be a potential target for the treatment of glioma. GSK1904529A is a small molecule inhibitor of IGF-1R and has been demonstrated to inhibit the proliferation of several tumor cells by inhibiting receptor phosphorylation and downstream signaling (15) . In the present study, the antitumor activity of GSK1904529A in glioma was assessed. Evaluation of the effects of GSK1904529A on the viability, apoptosis and migration of glioma cells may elucidate its effect on glioma tumor growth in vivo and determine its potential for the treatment of glioma. Cell viability assay. The cells (1,000 cells/well) were seeded into 96-well plates in triplicate and incubated overnight at 37˚C. The cells were subsequently treated with GSK1904529A at the indicated concentrations for 24, 48 or 72 h, followed by analysis using a CellTiter-Glo assay kit (Promega, Madison, WI, USA), according to the manufacturer's instructions.
Materials and methods

Reagents
Flow cytometry. The cells were treated with indicated concentrations of GSK1904529A for 48 h and were subsequently harvested and stained with propidium iodide using a Cycletest Plus DNA reagent kit (BD Biosciences, Franklin Lakes, NJ, USA), followed by analysis of the DNA content using a FACSCalibur (BD Biosciences) and CellQuest Pro software version 5.1 (BD Biosciences).
Apoptosis assay. Tumor samples, resected from mice, were fixed with fresh 10% formaldehyde and embedded into paraffin blocks. Cryosections were then prepared using a cryostat (CM1100; Leica Biosystems, Milton Keynes, UK). For terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, the in situ cell death detection kit, TMR red (Roche Diagnostics, Madison, WI, USA) was used, according to the manufacturer's instructions. The nuclei were stained using Hoechst (Invitrogen Life Technologies, Carlsbad, CA, USA) for 20 min. Images were then captured using a fluorescent microscope (TE2000-E; Nikon Instruments, Melville, NY, USA). The animal experiments were approved by the Institutional Animal Care and Use Committee of Zhengzhou University (Zhengzhou, China).
Transwell migration assay. A total of 1x10
5 cells were seeded into the upper chamber of a 24-transwell Boyden chamber wells (Corning Incorporated, Corning, NY, USA) in serum-free complete DMEM in the absence or presence of various concentrations of GSK1904529A. Serum-free complete DMEM, supplemented with 20 µg/ml fibronectin, was added to the lower chambers and used as a chemoattractant. The cells were treated with the indicated concentrations of GSK1904529A for 8 h and were subsequently fixed and stained using 0.1% crystal violet. The non-migrating cells on the upper chambers were removed and images of the migrated cells on the lower chambers were captured using a microscope in at least five randomly selected fields. The number of migrated cells were quantified and the inhibition of migration was calculated against the control group (no drug treatment).
In vivo tumor investigation. A total of 2x10 6 U87MG cells were implanted subcutaneously into the axillary flank of 16 female Balb/cA-nu mice aged 6-8 week (Shanghai Experimental Animal Center, Chinese Academy of Sciences, Shanghai, China). The animals were reared in a standard clean mouse facility. When the tumors reached 70 mm 3 in size, the mice were randomly divided into a control group and GSK1904529A-treatment groups (6 mice/group). The mice in the GSK1904529A-treatment group received either 10 or 20 mg/kg GSK1904529A daily, and the control group received the same volume of vehicle control. The tumor volumes and body weights of the mice were measured daily. The tumor volume was calculated according to the following formula: (mm 3 ) = 0.5 x (width x width x length).
Statistical analysis. The measurement results of tumors in the drug treatment groups were compared with those of the control group (no drug treatment) at each time point and unpaired Student's t-test was used for the comparison of each time point. Statistical analysis was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). The differences between each drug treatment group (10 and 20 mg/kg) and the control were statistically significant (P<0.05) for day 7, day 9 and day 11. P<0.05 was considered to indicate a statistically significant difference.
Results
GSK1904529A suppresses glioma cell viability. IGF/IGF-1R
signaling contributes to the growth and survival of tumor cells (10) . Therefore, the present study examined the effect of GSK1904529A on glioma cell viability. U87MG cells, commonly used human glioblastoma cells, were treated with increased concentrations of GSK1904529A and cell viability was determined. The data demonstrated that GSK1904529A significantly reduced the viability of U87MG cells in a dose-dependent manner, with a half-maximal inhibitory concentration (IC 50 ) of ~50 nM (Fig. 1A) . This suppression also increased as the duration of incubation increased (Fig. 1B) . These data suggested that the U87MG cells were highly sensitive to inhibition by GSK1904529A.
GSK1904529A induces the apoptosis of glioma cells.
IGF/IGF-1R signaling has been demonstrated to protect cells from apoptosis (16) . The present study examined the effect of GSK1904529A on the apoptosis of glioma cells. The U87MG cells were treated with increasing concentrations of GSK1904529A. The sub-G1 DNA content was determined using flow cytometry and was used to measure apoptosis. The data revealed that treatment with GSK1904529A significantly increased the sub-G1 DNA content in a dose-dependent manner ( Fig. 2A) . To confirm that apoptosis was induced by GSK1904529A, Hoechst staining was performed. The GSK1904529A-treated U87MG cells exhibited condensed and fragmented nuclei (Fig. 2B) . The number of cells with an apoptotic morphology increased in a dose-dependent manner (Fig. 2C) . Taken together, these data suggested that GSK1904529A markedly induced the apoptosis of glioma cells.
GSK1904529A inhibits the migration of glioma cells.
Glioma is a highly diffusely infiltrative disease. Motility is an important process, which contributes to glioma cell infiltration. It has been demonstrated that IGF/IGF-1R signaling stimulates motility in malignant cells (17) . Therefore, the present study determined the effect of GSK1904529A on glioma cell migration. A Transwell migration assay was performed in the presence of increasing concentrations of GSK1904529A. As shown in Fig. 3A and B, the migration of the U87MG cells was significantly inhibited by treatment with GSK1904529A, and the inhibition occurred in a dose-dependent manner. These data suggested that GSK1904529A antagonized IGF/IGF-1R-stimulated glioma cell motility.
GSK1904529A suppresses glioma tumor growth in vivo.
As the present study demonstrated that GSK1904529A exhibited antitumor activity in vitro, the effect of GSK1904529A on tumor growth in vivo was determined. The U87MG cells were inoculated subcutaneously into the axillary regions of mice. Following tumor establishment, the mice were treated with GSK1904529A or vehicle control and the tumor volume was monitored. The data revealed that the mice treated with GSK1904529A exhibited substantially reduced tumor volumes compared with the vehicle-treated group (Fig. 4A) . The suppression of tumor growth was correlated with the dose of GSK1904529A (Fig. 4A) . In addition, the treatment was well Figure 1 . GSK1904529A suppresses glioma cell viability. (A) U87MG cells were treated with GSK1904529A (6.25-400 nM) for 72 h, followed by measurement of cell viability using a viability assay. (B) U87MG cells were treated with GSK1904529A (100 nM) for 24, 48 or 72 h, followed by measurement of the effects on the inhibition of viability. Data are expressed as the mean ± standard deviation. tolerated, as no weight loss was observed (Fig. 4B) . Further investigation revealed that treatment with GSK1904529A induced marked apoptosis in the tumor cells (Fig. 4C) , which was consistent with the in vitro data. Taken together, these data suggested that GSK1904529A markedly inhibited glioma tumor growth in vivo.
Discussion
Malignant gliomas have a particularly poor prognosis and is, therefore, a disease of significant concern. Efforts have been made to develop novel compounds and chemotherapeutics, however, these are focused on a limited number of targets, including epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) (18) . IGF/IGF-1R signaling has been implicated in malignant gliomas, suggesting it a potential therapeutic target. IGF antisense therapies are currently under evaluation in clinical trials (10) . In the present study, the antitumor activity of a small-molecule inhibitor of IGF-1R, GSK1904529A, in glioma was assessed. The results demonstrated that GSK1904529A inhibited tumor growth in vitro and in vivo by inducing tumor cell apoptosis and inhibiting tumor cell migration. These results suggested that GSK1904529A is an effective compound for targeting IGF-1R and for the treatment of malignant gliomas.
Gliomas are a type of brain tumor, and the presence of the blood-brain barrier increases the difficulty for chemotherapeutic drugs to access the tumor. Further physiological investigations are required by introducing tumors into the brain to further assess the efficacy of GSK1904529A in the treatment of gliomas. With the development of increasing numbers of chemotherapeutic compounds, the combined therapy of GSK1904529A with other compounds may also be evaluated in the future studies.
In conclusion, the present study suggested the importance of the IGF/IGF-1R signaling pathway for the treatment of glioma. In addition, the results indicated that GSK1904529A may be a promising candidate for the treatment of glioma.
